---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035437"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:58:11.514720+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma

## Summary
- In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.
- NXC-201 showed 85% ORR and 71% CR/sCR in 20 relapsed/refractory multiple myeloma patients; 100% ORR and organ response in AL amyloidosis.
- Zero neurotoxicity observed; median CRS duration of 2 days at therapeutic dose, supporting potential outpatient use.
- Financial terms: $1.5M upfront, $50k annual fee, mid-single digit royalties, up to $20M sales milestones.
- Formed wholly-owned subsidiary Nexcella to develop NXC-201; expects minimal impact on Immix financials as Nexcella independently financed.

## SEC filing metadata
- accession: 0001493152-22-035437
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/0001493152-22-035437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035437
- JSON: https://secwatch.observer/filing/0001493152-22-035437.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035437.txt

## Key facts
- Material Agreements
  Immix Biopharma, Inc. entered into Research and License Agreement with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. valued at $1,500,000 (effective 2022-12-08).
  - Action: entry
  - Agreement: license
  - Counterparty: Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd.
  - Value: $1,500,000
  - Effective: 2022-12-08
  source text: On December 8, 2022, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.) (“Nexcella”), a wholly-owned subsidiary of Immix Biopharma, Inc. (the “Company”) entered into a Research and License Agreement (the “Agreement”) with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. (collectively, the “Licensors”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/0001493152-22-035437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.